文献速递心脑血管急症儿科与产科急症重症综合管理与镇静镇痛

儿童心脏骤停后综合征血清生物标志物的探索性评估

An exploratory assessment of serum biomarkers of post-cardiac arrest syndrome in children.
PubMed 文献 · Resuscitation · 2021-07-14
一句话结论儿童心脏骤停后初始血清CNTF和IL-17水平与6个月不良神经预后独立相关(AUC均为0.84),但尚需进一步验证。

这项前瞻性观察性单中心研究纳入42例心脏骤停后存活至ICU的儿童,在骤停后0-96小时内每24小时采血两次、约196小时采血一次,用Luminex多重珠免疫分析法检测炎症介质、激素和生长因子。主要终点为6个月PCPC评分(1-3为良好,4-6或较基线增加>1为不良)。初始CNTF和IL-17水平对良好与不良预后的分类AUC均为0.84(95%CI 0.73-0.96/0.73-0.97,p<0.001),多变量分析中仍与6个月PCPC相关;IP-10、CNTF和HGF的峰值水平也与预后独立相关。

要点

  • 在42例骤停后存活至ICU的儿童中,初始血清CNTF和IL-17对6个月不良神经预后(PCPC 4-6或较基线增加>1)的AUC均为0.84(95%CI 0.73-0.96和0.73-0.97,p<0.001)。
  • 多变量分析中初始CNTF和IL-17水平仍与6个月PCPC独立相关;IP-10、CNTF和HGF的峰值水平也与预后独立相关。
  • 18例(42%)在6个月随访前死亡;研究为单中心探索性设计,样本量小,生物标志物的预后效用尚需进一步研究验证。
  • 采血时间窗为骤停后0-96小时内每24小时两次、约196小时一次,标志物检测采用Luminex多重珠免疫分析法。

适用人群与场景

  • 儿童(院内或院外心脏骤停后存活至ICU)纳入本研究;中位年龄2.5岁(IQR 0.4-10.2),50%为女性。

诊断标准与关键阈值

  • 预后评估采用6个月时小儿脑功能分类(PCPC)评分:PCPC 1-3为良好结局,PCPC 4-6或较基线增加>1为不良结局。
  • 初始CNTF和IL-17水平对不良结局的ROC曲线AUC均为0.84(CNTF 95%CI 0.73-0.96,IL-17 95%CI 0.73-0.97,p均<0.001)。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:前瞻性观察性单中心研究;样本量42例儿童,无多中心;人群为心脏骤停后存活至ICU的儿童。
  • 主要终点:6个月PCPC良好(1-3)vs不良(4-6或较基线增加>1);初始CNTF AUC 0.84(95%CI 0.73-0.96,p<0.001),初始IL-17 AUC 0.84(95%CI 0.73-0.97,p<0.001)。
  • 多变量分析:初始CNTF和IL-17水平仍与6个月PCPC独立相关;峰值IP-10、CNTF和HGF水平也与结局独立相关。
  • 42例中18例(42%)在6个月随访前死亡。

证据类型、等级与局限

  • 证据类型:前瞻性观察性单中心探索性研究;原文未给出证据等级或推荐强度。
  • 局限:单中心、样本量小(42例)、观察性设计;原文结论称需进一步研究验证CNTF和IL-17的预后效用及病理生理作用。

对床旁实践的改变

  • 原文结果为探索性关联,尚不能作为床旁常规预后判断或决策依据;不能据此改变现有心脏骤停后儿童的管理流程。
  • 初始CNTF和IL-17与6个月不良神经预后相关,但AUC来自单中心小样本,需进一步验证后才可能用于预后评估。

指南或共识出处

  • 原文未提及指南或共识;研究注册于clinicaltrials.gov(NCT00797680),注册题目为「Duration of Hypothermia for Neuroprotection after Pediatric Cardiac Arrest: A Randomized, Controlled Trial」。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

AIM: We hypothesized that serum biomarkers of inflammation including chemokine, cytokine, pituitary hormones, and growth factors following cardiac arrest in children would independently associate with 6-month neurologic outcome.

METHODS: In this prospective observational single center study of children with in-hospital and out-of-hospital cardiac arrest surviving to intensive care unit admission, serum was obtained twice per 24 h period between 0 h and 96 h and once at approximately 196 h post-cardiac arrest. Inflammatory mediators, hormones, and growth factors were analyzed by Luminex Multiplex Bead Immunoassay. We recorded demographics, resuscitation characteristics, and Pediatric Cerebral Performance Category (PCPC) at 6 months. We analyzed the association and area under the curve (AUC) of biomarker levels with favorable (PCPC 1-3) or unfavorable (PCPC 4-6, or >1 increase from baseline) outcome.

RESULTS: Forty-two children (50% female; median age of 2.5 [IQR: 0.4-10.2]) were enrolled and 18 (42%) died prior to 6-month follow up. Receiver operator curves for initial levels of ciliary neurotrophic factor (CNTF, AUC 0.84, 95% CI 0.73-0.96, p < 0.001) and interleukin (IL-17, AUC 0.84, 95% CI 0.73-0.97, p < 0.001) best classified favorable versus unfavorable 6-month outcome. In multivariable analysis, initial levels of CNTF and IL-17 remained associated with 6-month PCPC. Peak levels of interferon-γ-inducible protein 10 (IP-10), CNTF, and hepatocyte growth factor (HGF) were also independently associated with outcome.

CONCLUSION: Increased serum concentrations of CNTF and IL-17 associated with unfavorable 6-month neurologic outcome of children surviving cardiac arrest. Further investigation of the prognostic utility and roles of CNTF and IL-17 in the pathophysiology of post-cardiac arrest syndrome are warranted. This project is registered with clinicaltrials.gov (NCT00797680) as "Duration of Hypothermia for Neuroprotection after Pediatric Cardiac Arrest: A Randomized, Controlled Trial".

来源:Resuscitation,查看原文。版权归原作者所有。

参考来源

  1. Kernan KF, Berger RP, Clark RSB, et al. An exploratory assessment of serum biomarkers of post-cardiac arrest syndrome in children. Resuscitation. 2021. PMID: 34271122. doi:10.1016/j.resuscitation.2021.07.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。